640 filings
Page 13 of 32
S-8
spv907g5mukir8rg l7
4 Oct 17
Registration of securities for employees
12:00am
8-K
lz2cynawrh3y3
28 Sep 17
ZIOPHARM Oncology Appoints David Mauney, M.D., as EVP and Chief Business
12:00am
8-K
cp649hkwfq8 he00
31 Jul 17
Results of Operations and Financial Condition
12:00am
8-K
bi05517nsoqg02qsbz7
15 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
21sjl qcu
5 Jun 17
ZIOPHARM Oncology Announces Positive Updated Results ofAd-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting
12:00am
8-K
nti4z6
12 May 17
Ziopharm Oncology Announces Pricing of $50 Millionfollow-on Offering of Common Stock
12:00am
424B5
6iaofyuzzdlf5xsuarxg
12 May 17
Prospectus supplement for primary offering
12:00am
8-K
jqt2roufwj9v4p0gj3
2 May 17
ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-SpecificCAR-T Cell
12:00am
8-K
wc2rjcqywp1
1 May 17
ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities
12:00am
DEFA14A
ys3gyz1yna3r7ifq
28 Apr 17
Additional proxy soliciting materials
12:00am
8-K
titj82x0jbz62l
27 Mar 17
ZIOPHARM Announces SuccessfulEnd-of-Phase 2 Meeting with FDA forAd-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma
12:00am
8-K
vjxzy0yge6zxxx vs1
16 Feb 17
ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities
12:00am
8-K
wt4m61un 61yv
11 Jan 17
Regulation FD Disclosure
12:00am
8-K
0tlynu
10 Jan 17
Regulation FD Disclosure
12:00am
UPLOAD
0eb5tjlulgzf5tchv
4 Jan 17
Letter from SEC
12:00am
CORRESP
d0n64jf
12 Dec 16
Correspondence with SEC
12:00am